Thursday, 17 March 2011 Poster Session I. Epidemiology/Prevention/Diagnosis S27

Methods: We retrospectively reviewed 120 patients who were clas-sified as having triple-negative breast cancer (by immunohistochemicaltechnique). The all of them came from 4 public hospitals and 3 privatehospitals in Bangkok between January 2000 and October 2010.The patientcharacteristics, tumor characteristics, and treatment outcomes had beencollected, then mapping with demographic data, staging, and treatentoutcome. The simple Cox proportional hazard model was used to identifyindependent prognostic factors in our study.

Results: The median follow up time for all patients was 18 months(range, 2−75 months). 120 patients were classified as having triple-negative breast cancer. Among these, 70 patients (58.33%) had pre-menopausal status and 92 patients were classified as having early breastcancers. The majority of cases (n = 119) were invasive ductal carcinoma.Eleven of them had vascular involvement. During a median follow-uptime of 5 years, 8 patients experienced relapse, of which 2 were localrelapses and 6 were distant relapses (brain and lung metastasis). At theend of the study, 110 of 120 are not metastasis till the censored date(31 October 2010). The 5 years disease free overall survival (DFS) is74.50% (95%CI: 55.31 to 86.38). Hazard ratio for locally advanced toearly breast is 2.45 (95%CI: 0.58 to 10.38). The 5-year survival ratewas 63.77% (95%CI: 20.07 to 88.16) for locally advanced and 80.77%(95%CI: 58.40 to 91.87) for early breast cancer. Regarding bi-variableanalysis by Cox proportional hazard model, we found that no factors reachthe peak of hazard ratio (HR) when each group was compared, exceptfor vascular/perineural involvement. The patients with vascular/perineuralinvolvement had increased risk of relapse (HR=11.58, 95%CI: 2.83 to47.39, p-value <0.001).

Conclusion: Triple-negative breast cancer is an aggressive disease withrelatively poor survival. One who had vascular and perineural involvementassociated with short term survival. Therefore, we would like to concludedthat vascular and perineural involvement might be poor prognostic factorin this our data.Disclosure of Interest: None Declared

P139 The clinical features and prognosis of tubular breast cancer

M. Izquierdo1, A. Alsina1, R. Fernandez1, S. Baulies1, F. Tresserra2,N. Rodriguez3, R. Fabregas1, M. Cusido1, C. Ara1. 1Gynaecology,2Histology, 3Epidemiology, DEXEUS, Barcelona, Spain

Goals: Compare the clinical features and prognosis of Tubular breastcancer with Ductal breast cancer grade I.

Methods: Analyzed all Tubular breast cancer studied in Breast DiseasesCommittee during the period 1990–2009, comparing the clinical featuresand prognosis of Tubular breast cancer with Ductal breast cancer grade I,the free disease survival were analyzed with Kaplan–Meier curves.

Results: Studied 140 cases, 39 (26.2%) Tubular Breast Cancer and 110(73.8%) Ductal Breast Cancer Grade I. Tubular breast cancer was 1.18%of the breast cancer in the Breast Cancer Committee. No differences inthe average age of patients with Tubular Breast Cancer and Breast CancerGrade I (51.64 versus 52.11), family history, parity, fertility treatment, nul-liparous, menopausal status, tumour size, hormonal and HER2 receptors.In Tubular carcinomas disease free survival at 5 years was 97% and 93%

at 10 years. In Ductal Breast Grade I carcinomas disease free survival at5 years was 95% and 89% at 10 years.

Conclusion: Tubular breast cancer is a specific type of breast cancerwith an excellent prognostic and survival.Disclosure of Interest: None Declared

P140 Do medullary breast cancer patients have better prognosis

compared to patients with breast cancer of other tumor

types?

V. Posarac1, S. Susnjar2, D. Jovanovic3, M. Jevric1. 1Department ofSurgical Oncology, 2Department of Medical Oncology, 3Department ofPathology, Institute for Oncology and Radiology of Serbia, Belgrade,Serbia

Goals: Medullary histology is a rare type of breast cancer (BC) and itis generally thought that patients (pts) with medullary BC did better incomparison to pts with other BC histology types. The aim of our analysiswas to compare the disease outcome between node-negative medullaryand non-medullary early BC pts.

Methods: We analyzed grade 3 node negative BC pts who werediagnosed between 1987 and 1997 and treated with radical surgery ±postoperative radiotherapy (PRT). None of them received adjuvant sys-temic therapy. Steroid receptors’ contents were determined prospectivelyby biochemical methods with cut off limits for ER and PR set on 10fmol/mg prn and 20 fmol/mg prn, respectively. Main objective was diseasefree survival (DFS) and overall survival (OS). Statistical analysis includesPearson Chi squared, Fisher Exact and Log rank tests.

Results: We identified 53 grade 3 medullary node-negative early BCpatients, median age of 48 years (range 29−68) and 25 grade 3 node-negative pts with other types of BC, median age of 56 years (range 32−73).The median follow-up for the whole group was 8 years (range 0.4–24.8).The groups were well balanced for tumor size, SR status, and double-negative SR status (ER0/PR0), as well. Also, there was no difference innumber of pts treated with PRT between the two groups. Fifteen out of53 (28%) medullary BC pts experienced disease relapse in contrast to18/25 (72%) non-medullary BC pts and this difference was statisticallysignificant (Pearson Chi-squared Test, p = 0.0003). Disease-free survivaland OS were significantly higher in medullary BC pts compared to non-medullary BC pts (Log rank Test, p<0.05 for both).

Conclusion: Although obtained on a small number of pts, our resultsseemed to confirm that medullary BC pts had better prognosis in compar-ison to pts with other types of BC.Disclosure of Interest: None Declared

P141 Mucinous carcinoma of the breast

S.Y. Bae1, J.-H. Yang1, S.J. Nam1, J.E. Lee1, S.K. Lee1, M.Y. Koo1,M.-Y. Choi1, D.H. Cho1. 1Samsung Medical Center, Seoul, Korea,Republic of

Goals: Mucinous carcinoma (MC) of the breast is a rare histologic type ofmammary neoplasm. The objective of this study was to evaluate the longterm disease free and overall survival as well as the significance of theavailable clinical and pathological prognostic factors for MC.

Methods: A retrospective analysis of all MC cases reported in the Sam-sung Medical center database between 1997 and 2007 was conducted.Overall survival (OS) and disease free survival (DFS) were calculated at 5and 10 years of follow up. Clinicopathological characteristics and survivalsof 268 MC patients were retrospectively reviewed and compared with thoseof 2,455 IDC-NOS. The prognostic significance of gender, age at diagnosis,T and N status, estrogen and progesterone receptors, HER2 and adjuvanttherapy was calculated by univariate and multivariate analysis.

Results: The median age at diagnosis was 44 yr (Range 28−87 yr) inMC and 47 yr (Range 21−84 yr) in IDC-NOS. The MC cases showed a lessinvolvement of lymph node, lower stage, more expression of hormonalreceptors and less HER-2 overexpression when compared to the IDC-NOS cases of the same period. Kaplan–Meier survival curves revealedthat the 5 years overall survival (OS) rate of MC was 95.2% and 10 yearssurvival were 83%. It compared to 94.9% (5 year) and 81.8% (10 year)for IDC-NOS. Multivariate analysis by Cox regression revealed the nodalstatus (N stage) to be the most significant prognostic factor followed byadjuvant chemotherapy and adjuvant hormonal therapy. The addition ofradiation therapy after surgery did not significantly improve overall survival.The 5 years DFS rate of mucinous carcinoma was 95.2% and 10 yearssurvival were 58.2%. Multivariate analysis for DFS revealed the nodalstatus, adjuvant hormonal therapy and pure type MC were statisticallysignificant prognostic factors.

Conclusion: Mucinous carcinoma in Koreans presents in younger pa-tients than in IDC-NOS and showed favorable characteristics including lessinvolvement of lymph node, lower stage, more expression of hormonalreceptors, less HER-2 overexpression. It has been associated with a betterDFS than IDC-NOS, but it has a similar overall survival. Nodal status andadjuvant therapy appear to be the most significant predictor of prognosisthan a histologic type.Disclosure of Interest: None Declared